Novavax announced that its vaccine against the CCP virus was shown to be 89.3 percent effective in preventing the COVID-19 disease in a trial in the United Kingdom, but less effective in South Africa where a different virus variant is more prevalent. “Strong efficacy in Phase 3 UK trial with over 50 % of cases attributable to the now-predominant UK variant and the remainder attributable to COVID-19 virus,” the company announced on its website. The company on a conference call noted that this was interim data, and executives said they expect it will be two to three months before they are ready to apply for authorization with regulators in Britain, the European Union, and other countries. UK Prime Minister Boris Johnson said that if the vaccine is approved, there will be 60 million cases on order. The trial, which is still underway, enrolled more than 15,000 people aged 18 to 84, …